<DOC>
	<DOCNO>NCT00354510</DOCNO>
	<brief_summary>The purpose study investigate clinical efficacy 3 % ( w/w ) GW842470X cream apply involved skin adult patient moderate atopic dermatitis use Eczema Area Severity Index ( EASI ) assessment disease severity investigate safety tolerability 3 % GW842470X cream diseased skin adult patient .</brief_summary>
	<brief_title>Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Inclusion criterion : Moderate atopic dermatitis patient ( IGA=3 ) . The disease involvement must &gt; 5 % body surface area . Female patient childbearing potential must use appropriate method contraception . Exclusion criterion : Patients active skin disease atopic dermatitis eligible . Patients systemic treatment atopic dermatitis topical transdermal treatment ( nicotine , hormone replacement therapy ) within 14 day prior first application study medication and/or topical treatment tar , corticosteroid , topical immunomodulators oral treatment corticosteroid within 10 day prior first application and/or oral antihistamine within 5 day first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>atopic dermatitis</keyword>
	<keyword>GW842470X</keyword>
	<keyword>PDE4 inhibitor</keyword>
</DOC>